ROS-sensitive calcipotriol nano-micelles prepared by methoxypolyethylene glycol (mPEG) - modified polymer for the treatment of psoriasis.

IF 6.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Delivery Pub Date : 2022-12-01 DOI:10.1080/10717544.2022.2086944

Yulin Hua, Tiantian Chang, Kun Jiang, Jinhong Wang, Xiaodong Cui, Min Cheng, Fang Yan, Bo Song, Yuzhen Wang

{"title":"ROS-sensitive calcipotriol nano-micelles prepared by methoxypolyethylene glycol (mPEG) - modified polymer for the treatment of psoriasis.","authors":"Yulin Hua, Tiantian Chang, Kun Jiang, Jinhong Wang, Xiaodong Cui, Min Cheng, Fang Yan, Bo Song, Yuzhen Wang","doi":"10.1080/10717544.2022.2086944","DOIUrl":null,"url":null,"abstract":"<p><p>Oxidative stress due to excessive reactive oxygen species (ROS) production in the skin microenvironment is one of the main mechanisms in psoriasis pathogenesis. A nano drug delivery system based on ROS-responsive release can enhance drug release at the target site. In this study, a ROS-sensitive material methoxypolyethylene glycol-thioether-thiol (mPEG-SS) was synthesized using mPEG as the parent structure with sulfide structural modification. An mPEG-SS-calcipotriol (mPEG-SS-CPT, PSC) nano-micelle percutaneous delivery system was prepared by encapsulating CPT. A small animal imaging system was used to study PSC's the ROS-sensitive drug release process. It is shown that endogenous ROS mainly affects PSC and releases drugs. Finally, the therapeutic effect of PSC on psoriasis was explored by animal experiments. Ultimately, it ameliorates imiquimod-induced psoriasis-like inflammation. Overall, PSC is an effective ROS-sensitive transdermal drug delivery system that is expected to provide a new strategy for treating psoriasis.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":null,"pages":null},"PeriodicalIF":6.5000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246247/pdf/","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10717544.2022.2086944","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 8

Abstract

Oxidative stress due to excessive reactive oxygen species (ROS) production in the skin microenvironment is one of the main mechanisms in psoriasis pathogenesis. A nano drug delivery system based on ROS-responsive release can enhance drug release at the target site. In this study, a ROS-sensitive material methoxypolyethylene glycol-thioether-thiol (mPEG-SS) was synthesized using mPEG as the parent structure with sulfide structural modification. An mPEG-SS-calcipotriol (mPEG-SS-CPT, PSC) nano-micelle percutaneous delivery system was prepared by encapsulating CPT. A small animal imaging system was used to study PSC's the ROS-sensitive drug release process. It is shown that endogenous ROS mainly affects PSC and releases drugs. Finally, the therapeutic effect of PSC on psoriasis was explored by animal experiments. Ultimately, it ameliorates imiquimod-induced psoriasis-like inflammation. Overall, PSC is an effective ROS-sensitive transdermal drug delivery system that is expected to provide a new strategy for treating psoriasis.

Abstract Image

查看原文本刊更多论文

甲氧基聚乙二醇(mPEG)修饰聚合物制备的ros敏感钙三醇纳米胶束治疗银屑病。

皮肤微环境中活性氧(ROS)产生过多引起的氧化应激是银屑病发病的主要机制之一。基于ros反应释放的纳米给药系统可以增强药物在靶点的释放。本研究以mPEG为母体结构，经硫化物结构修饰，合成了一种对ros敏感的甲氧基聚乙二醇硫醚硫醇(mPEG- ss)材料。通过包封CPT制备了mpeg - ss -钙化三醇(mPEG-SS-CPT, PSC)纳米胶束经皮给药体系。采用小动物成像系统研究PSC对ros敏感的药物释放过程。结果表明，内源性ROS主要影响PSC并释放药物。最后，通过动物实验探讨PSC对银屑病的治疗作用。最终，它改善了吡喹莫德引起的牛皮癣样炎症。总之，PSC是一种有效的ros敏感的经皮给药系统，有望为治疗银屑病提供新的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Delivery 医学-药学

CiteScore

11.80

自引率

5.00%

发文量

250

审稿时长

3.3 months

期刊介绍： Drug Delivery is an open access journal serving the academic and industrial communities with peer reviewed coverage of basic research, development, and application principles of drug delivery and targeting at molecular, cellular, and higher levels. Topics covered include all delivery systems including oral, pulmonary, nasal, parenteral and transdermal, and modes of entry such as controlled release systems; microcapsules, liposomes, vesicles, and macromolecular conjugates; antibody targeting; protein/peptide delivery; DNA, oligonucleotide and siRNA delivery. Papers on drug dosage forms and their optimization will not be considered unless they directly relate to the original drug delivery issues. Published articles present original research and critical reviews.